Cancer pharmacogenomics

International trends

Yasuko Yamayoshi, Emiko Iida, Yusuke Tanigawara

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalInternational Journal of Clinical Oncology
Volume10
Issue number1
DOIs
Publication statusPublished - 2005 Feb

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Neoplasms
DNA Repair Enzymes
Therapeutic Uses
Genetic Polymorphisms
Enzymes
Drug-Related Side Effects and Adverse Reactions
Pharmacokinetics
Diet
Drug Therapy
Mutation
Genes

Keywords

  • Drug response
  • Drug toxicity
  • Genetic polymorphisms
  • Pharmacogenomics
  • PK/PD
  • Therapeutic effect

ASJC Scopus subject areas

  • Oncology

Cite this

Cancer pharmacogenomics : International trends. / Yamayoshi, Yasuko; Iida, Emiko; Tanigawara, Yusuke.

In: International Journal of Clinical Oncology, Vol. 10, No. 1, 02.2005, p. 5-13.

Research output: Contribution to journalArticle

Yamayoshi, Yasuko ; Iida, Emiko ; Tanigawara, Yusuke. / Cancer pharmacogenomics : International trends. In: International Journal of Clinical Oncology. 2005 ; Vol. 10, No. 1. pp. 5-13.
@article{0d96bfbb9cca444eaec80609d796cca9,
title = "Cancer pharmacogenomics: International trends",
abstract = "It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.",
keywords = "Drug response, Drug toxicity, Genetic polymorphisms, Pharmacogenomics, PK/PD, Therapeutic effect",
author = "Yasuko Yamayoshi and Emiko Iida and Yusuke Tanigawara",
year = "2005",
month = "2",
doi = "10.1007/s10147-004-0467-4",
language = "English",
volume = "10",
pages = "5--13",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Cancer pharmacogenomics

T2 - International trends

AU - Yamayoshi, Yasuko

AU - Iida, Emiko

AU - Tanigawara, Yusuke

PY - 2005/2

Y1 - 2005/2

N2 - It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.

AB - It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.

KW - Drug response

KW - Drug toxicity

KW - Genetic polymorphisms

KW - Pharmacogenomics

KW - PK/PD

KW - Therapeutic effect

UR - http://www.scopus.com/inward/record.url?scp=15044361184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044361184&partnerID=8YFLogxK

U2 - 10.1007/s10147-004-0467-4

DO - 10.1007/s10147-004-0467-4

M3 - Article

VL - 10

SP - 5

EP - 13

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -